Loading clinical trials...
Loading clinical trials...
A Phase 1b Study of REOLYSIN® (Reovirus Serotype 3 - Dearing Strain) Combined With Standard Doses of Bortezomib and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Conditions
Interventions
Bortezomib
Dexamethasone
+3 more
Locations
1
United States
USC / Norris Comprehensive Cancer Center
Los Angeles, California, United States
Start Date
August 21, 2015
Primary Completion Date
April 19, 2022
Completion Date
April 19, 2022
Last Updated
August 14, 2023
NCT05312255
NCT04508790
NCT04640779
NCT04850599
NCT04756401
NCT05288062
Lead Sponsor
University of Southern California
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions